174 related articles for article (PubMed ID: 17298295)
1. Targeting the Wnt signaling pathway to treat Barrett's esophagus.
Clément G; Jablons DM; Benhattar J
Expert Opin Ther Targets; 2007 Mar; 11(3):375-89. PubMed ID: 17298295
[TBL] [Abstract][Full Text] [Related]
2. In-depth characterization of the Wnt-signaling/β-catenin pathway in an in vitro model of Barrett's sequence.
Götzel K; Chemnitzer O; Maurer L; Dietrich A; Eichfeld U; Lyros O; Moulla Y; Niebisch S; Mehdorn M; Jansen-Winkeln B; Vieth M; Hoffmeister A; Gockel I; Thieme R
BMC Gastroenterol; 2019 Mar; 19(1):38. PubMed ID: 30841855
[TBL] [Abstract][Full Text] [Related]
3. Alterations of the Wnt signaling pathway during the neoplastic progression of Barrett's esophagus.
Clément G; Braunschweig R; Pasquier N; Bosman FT; Benhattar J
Oncogene; 2006 May; 25(21):3084-92. PubMed ID: 16407829
[TBL] [Abstract][Full Text] [Related]
4. Gastroesophageal reflux and Barrett's esophagus: a pathway to esophageal adenocarcinoma.
Schlottmann F; Molena D; Patti MG
Updates Surg; 2018 Sep; 70(3):339-342. PubMed ID: 30039277
[TBL] [Abstract][Full Text] [Related]
5. Trefoil factor 1 inhibits the development of esophageal adenocarcinoma from Barrett's epithelium.
Hasebe K; Yamazaki K; Yamaguchi J; Kokuryo T; Yokoyama Y; Miyata K; Fukaya M; Nagino M; Ebata T
Lab Invest; 2022 Aug; 102(8):885-895. PubMed ID: 35279702
[TBL] [Abstract][Full Text] [Related]
6. Response to TNF-α Is Increasing Along with the Progression in Barrett's Esophagus.
Chemnitzer O; Götzel K; Maurer L; Dietrich A; Eichfeld U; Lyros O; Jansen-Winkeln B; Hoffmeister A; Gockel I; Thieme R
Dig Dis Sci; 2017 Dec; 62(12):3391-3401. PubMed ID: 29086334
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic alteration of the Wnt inhibitory factor-1 promoter occurs early in the carcinogenesis of Barrett's esophagus.
Clément G; Guilleret I; He B; Yagui-Beltrán A; Lin YC; You L; Xu Z; Shi Y; Okamoto J; Benhattar J; Jablons D
Cancer Sci; 2008 Jan; 99(1):46-53. PubMed ID: 18005197
[TBL] [Abstract][Full Text] [Related]
8. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
9. Barrett's esophagus and esophageal adenocarcinoma.
Reid BJ
Gastroenterol Clin North Am; 1991 Dec; 20(4):817-34. PubMed ID: 1787015
[TBL] [Abstract][Full Text] [Related]
10. Origins of Metaplasia in Barrett's Esophagus: Is this an Esophageal Stem or Progenitor Cell Disease?
Zhang W; Wang DH
Dig Dis Sci; 2018 Aug; 63(8):2005-2012. PubMed ID: 29675663
[TBL] [Abstract][Full Text] [Related]
11. Biomarkers in Barrett's esophagus (review).
van Lieshout EM; Jansen JB; Peters WH
Int J Oncol; 1998 Oct; 13(4):855-64. PubMed ID: 9735417
[TBL] [Abstract][Full Text] [Related]
12. Targeting the COX1/2-Driven thromboxane A2 pathway suppresses Barrett's esophagus and esophageal adenocarcinoma development.
Zhang T; Wang Q; Ma WY; Wang K; Chang X; Johnson ML; Bai R; Bode AM; Foster NR; Falk GW; Limburg PJ; Iyer PG; Dong Z
EBioMedicine; 2019 Nov; 49():145-156. PubMed ID: 31707149
[TBL] [Abstract][Full Text] [Related]
13. Targeting the Hedgehog Pathway Using Itraconazole to Prevent Progression of Barrett's Esophagus to Invasive Esophageal Adenocarcinoma.
Kelly RJ; Ansari AM; Miyashita T; Zahurak M; Lay F; Ahmed AK; Born LJ; Pezhouh MK; Salimian KJ; Ng C; Matsangos AE; Stricker-Krongrad AH; Mukaisho KI; Marti GP; Chung CH; Canto MI; Rudek MA; Meltzer SJ; Harmon JW
Ann Surg; 2021 Jun; 273(6):e206-e213. PubMed ID: 31290765
[TBL] [Abstract][Full Text] [Related]
14. Bile acid-induced expression of activation-induced cytidine deaminase during the development of Barrett's oesophageal adenocarcinoma.
Morita S; Matsumoto Y; Okuyama S; Ono K; Kitamura Y; Tomori A; Oyama T; Amano Y; Kinoshita Y; Chiba T; Marusawa H
Carcinogenesis; 2011 Nov; 32(11):1706-12. PubMed ID: 21890457
[TBL] [Abstract][Full Text] [Related]
15. Expression profiles of cancer stem cell markers: CD133, CD44, Musashi-1 and EpCAM in the cardiac mucosa-Barrett's esophagus-early esophageal adenocarcinoma-advanced esophageal adenocarcinoma sequence.
Mokrowiecka A; Veits L; Falkeis C; Musial J; Kordek R; Lochowski M; Kozak J; Wierzchniewska-Lawska A; Vieth M; Malecka-Panas E
Pathol Res Pract; 2017 Mar; 213(3):205-209. PubMed ID: 28216140
[TBL] [Abstract][Full Text] [Related]
16. Acid, bile, and CDX: the ABCs of making Barrett's metaplasia.
Souza RF; Krishnan K; Spechler SJ
Am J Physiol Gastrointest Liver Physiol; 2008 Aug; 295(2):G211-8. PubMed ID: 18556417
[TBL] [Abstract][Full Text] [Related]
17. The pathogenesis of Barrett's metaplasia and the progression to esophageal adenocarcinoma.
Grotenhuis BA; van Lanschot JJ; Dinjens WN; Wijnhoven BP
Recent Results Cancer Res; 2010; 182():39-63. PubMed ID: 20676870
[TBL] [Abstract][Full Text] [Related]
18. A Systematic Review of Esophageal MicroRNA Markers for Diagnosis and Monitoring of Barrett's Esophagus.
Mallick R; Patnaik SK; Wani S; Bansal A
Dig Dis Sci; 2016 Apr; 61(4):1039-50. PubMed ID: 26572780
[TBL] [Abstract][Full Text] [Related]
19. Survivin, a potential biomarker in the development of Barrett's adenocarcinoma.
Vallböhmer D; Peters JH; Oh D; Kuramochi H; Shimizu D; Demeester SR; Hagen JA; Chandrasoma PT; Danenberg KD; DeMeester TR; Danenberg P
Surgery; 2005 Oct; 138(4):701-6; discussion 706-7. PubMed ID: 16269299
[TBL] [Abstract][Full Text] [Related]
20. Esophageal adenocarcinoma arising from Barrett's dysplasia: a case report of double occurrence and prolonged survival after chemotherapy.
Vats HS; Banerjee TK; Resnick J; Khan Q
Clin Med Res; 2006 Sep; 4(3):184-8. PubMed ID: 16988098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
